UK Markets open in 6 mins

Heidelberg Pharma AG (0QW5.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
4.6745-0.0373 (-0.79%)
At close: 03:23PM BST
Full screen
Previous close4.7118
Open4.7000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range4.6500 - 4.7000
52-week range4.6500 - 4.7000
Volume19,183
Avg. volumeN/A
Market cap120.508M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.7830
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure

    Heidelberg Pharma AG / Key word(s): Corporate ActionHeidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure 09-May-2022 / 16:39 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY

  • EQS Group

    Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022

    DGAP-News: Heidelberg Pharma AG / Key word(s): Interim ReportHeidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022 28.04.2022 / 07:14 The issuer is solely responsible for the content of this announcement.Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2022- Start of clinical trial with HDP-101 in multiple myeloma- Financing commitment of up to EUR 36 million obtained from main shareholder dievini- Signing of a strategic partnership w

  • EQS Group

    Heidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022

    DGAP-News: Heidelberg Pharma AG / Key word(s): Conference07.04.2022 / 14:05 The issuer is solely responsible for the content of this announcement.PRESS RELEASEHeidelberg Pharma to Present New Data on its Proprietary ATAC(R) Technology Platform at the AACR Annual Meeting 2022Ladenburg, Germany, 7 April 2022 - Heidelberg Pharma AG (FSE: HPHA) announced today that it will present preclinical data on its proprietary Amanitin-based ATAC(R) technology at the American Association for Cancer Research (A